Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines

S Okuno1, H Sato2, K Kuriyama-Matsumura2, M Tamba2, H Wang2, S Sohda1, H Hamada1, H Yoshikawa1, T Kondo2 and S Bannai*1,2
1Department of Obstetrics and Gynecology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan; 2Department of Biochemistry, Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan; *Department of Biochemistry and Molecular Biology in Disease, Atomic Disease Institute, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan

Transport system \( \text{x}^-\) is a member of plasma membrane heterodimeric amino-acid transporters and consists of two protein components, xCT and 4F2hc. This system mediates cystine entry coupled with the exodus of intracellular glutamate and regulates the intracellular glutathione (GSH) levels in most mammalian cultured cells. We studied the activity of system \( \text{x}^-\) and GSH content in human ovarian cancer cell line (A2780) and its cisplatin (CDDP)-resistant variant (A2780DDP). The rate of cystine uptake was approximately 4.5-fold higher in A2780DDP cells than in A2780 cells and the cystine uptake in A2780DDP cells was mediated by system \( \text{x}^-\). Intracellular GSH content was much higher in A2780DDP cells but it fell drastically in the presence of excess glutamate, which inhibited the cystine uptake competitively. xCT and 4F2hc mRNAs were definitely expressed in A2780DDP cells, but far less in A2780 cells. Expression of system \( \text{x}^-\) activity by transfection with cDNAs for xCT and 4F2hc made A2780 cells more resistant to CDDP. Similar results on the cystine uptake were obtained in human colon cancer cell lines. These findings suggest that the system \( \text{x}^-\) plays an important role in maintaining the higher levels of GSH and consequently in CDDP resistance in cancer cell lines.

Keywords: cystine; transporter; glutathione; drug resistance; cisplatin

Cisplatin (cis-diaminedichloroplatinum (II), CDDP) is one of the most widely used chemotherapeutic agents for the treatment of human ovarian cancer and other tumours (Rosenberg, 1985). CDDP is able to exert its cytotoxicity to ovarian cancer via the formation of intra- and interstrand CDDP-DNA adducts, which can ultimately result in cell cycle arrest at G1, S, or G2/M and the induction of genetically programmed cell death (Reed, 1998). One of the major problems with CDDP treatment is the clinical development of resistance to this drug (Perez et al, 1993). Although the mechanisms underlying tumour resistance to CDDP in vivo have not been understood clearly, in vitro studies on cell lines have shown that they are multifactorial. These include decreased drug transport, increased cellular detoxification because of increased glutathione (GSH), changes in DNA repair involving increased nucleotide excision repair and/or loss of mismatch repair, increased tolerance of DNA adducts, and alterations in the apoptotic cell death pathway (Andrews and Howell, 1990; Goto et al, 1995; Johnson et al, 1997; Li et al, 1999, 2001). However, there is abundant evidence showing that increase in GSH is a major factor in CDDP resistance and several CDDP-resistant cell lines keep the higher levels of GSH than the sensitive cell lines (Behrens et al, 1987; Mistry et al, 1991; Godwin et al, 1992).

The biosynthesis of GSH occurs in two ATP-dependent reactions (Meister, 1988). The first step is the synthesis of \( \gamma \)-glutamylcysteine (\( \gamma \)-GC) from cysteine and glutamate catalysed by \( \gamma \)-glutamylcysteine synthetase (\( \gamma \)-GCS). The second step is the synthesis of GSH from \( \gamma \)-GC and glycine catalysed by GSH synthetase. \( \gamma \)-GCS is the rate-limiting enzyme and the increase in its activity results in the increase in intracellular GSH. It has been shown that the activity of \( \gamma \)-GCS is higher in CDDP-resistant cells than in CDDP-sensitive cells and this may contribute to the high GSH levels in the former cells (Goto et al, 1995; Yao et al, 1995; Iida et al, 1999). Cysteine is an essential amino acid for many types of mammalian cultured cells, but it is unstable in the extracellular fluid, for example, in culture media and is rapidly autoxidised to cystine (Tooleby, 1975). Plasma membrane transport of amino acids is mediated by several transport systems (Christensen, 1990). We described previously in cultured mammalian cells an Na+-independent anionic amino-acid transport system, designated system \( \text{x}^-\), highly specific for cystine and glutamate (Bannai and Kitamura, 1980, 1981; Bannai, 1986). System \( \text{x}^-\) is a heterodimeric amino acid transporter consisting of two protein components named xCT and 4F2hc (Sato et al, 1999, 2000). Cystine taken up via system \( \text{x}^-\) is rapidly reduced to cysteine, which is used for the synthesis of GSH (Bannai and Ishii, 1982). Since intracellular cysteine is a rate-limiting precursor for GSH synthesis, the intracellular GSH level is regulated by the system \( \text{x}^-\) activity. In the present work, we have investigated the cystine transport activity in the CDDP-resistant and CDDP-sensitive human ovarian cancer cell lines.

*Correspondence: Dr S Bannai; s-bannai@md.tsukuba.ac.jp
Received 22 August 2002; revised 12 November 2002; accepted 25 November 2002
MATERIALS AND METHODS

Cell culture

Human ovarian cancer cell line (A2780) and its CDDP-resistant variant A2780DDP and human colon cancer cell line (HCT8 and its CDDP-resistant variant HCT8DDP) were donated by Dr K J Scanlon (Biochemical Pharmacology, City of Hope National Medical Center, Duarte, CA, USA). They were cultured in RPMI 1640 supplemented with 5% fetal bovine serum at 37°C in 5% CO2. The CDDP-resistant cells were treated with 100 μM CDDP (Nihon Kayaku Co., Tokyo, Japan) for 2 h every week as described (Iida et al, 1999).

Uptake of cystine

The uptake of cystine was measured by techniques described previously (Bannai and Kitamura, 1980). Cells were plated at 5 × 10^5 in a 35 mm diameter dish and cultured for 24 h. They were rinsed three times in warmed phosphate-buffered saline (pH 7.4) containing 0.9 mM CaCl2, 0.5 mM MgCl2 and 5.6 mM glucose (PBSG). The cells were then incubated in 0.5 ml of the prewarmed uptake medium for 2 min at 37°C. The uptake medium was PBSG containing [14C]cystine (NEN Life Science Products Inc., Boston, MA, USA) and this enhanced uptake was inhibited by glutamate (data not shown). The rate of cystine uptake in A2780DDP cells was mostly Na+- and Cl−-dependent and strongly inhibited by glutamate, but not by aspartate, leucine or arginine. The uptake of cystine in A2780DDP cells was approximately 4.5-fold higher in A2780DDP than that in A2780. To characterize the cystine transport system, cells were incubated for 24 h with medium, in which Na+ was replaced by choline. The uptake of cystine was not inhibited significantly by the amino acids tested.

Cytotoxicity of CDDP

The sensitivity of cells to CDDP was determined by dye exclusion method using nigrosin (Patterson, 1979).

Determination of intracellular glutathione

The glutathione content was measured by enzymatic method using nigrosin (Patterson, 1979). The glutathione content was measured by enzymatic method using nigrosin (Patterson, 1979). Total glutathione (GSH and GSSG) was extracted with 5% trichloroacetic acid. The glutathione content was measured by enzymatic method using nigrosin (Patterson, 1979).

Determination of intracellular cysteine

The cysteine content in the cells was determined by the method of Cotgreave and Moldeus (1986) with slight modifications. Briefly, the cells, plated at 5 × 10^5 in a 35 mm diameter dish and cultured for 24 h, were rinsed three times with PBSG and incubated in the dark at room temperature for 10 min with 100 μl of 8 mM monobromobimane in 50 mM N-ethylmorpholine, pH 8, and 100 μl of PBSG. Then 10 μl of 100% trichloroacetic acid was added. The protein precipitate was removed by centrifugation at 3000 g for 5 min and aliquots were analysed for cysteine-bimane adducts by HPLC. The HPLC separation was achieved on a steel column (4.6 mm × 100 mm) packed with 3 μm octadecylsila reversed-phase material purchased from Nacalai Tesque Inc., Kyoto, Japan. The fluorescence at 480 nm was monitored with the excitation at 394 nm. The elution was performed with 9.0% (v/v) acetonitrile in 0.25% (v/v) acetic acid, pH 3.7, for 8 min, and then with 75% (v/v) acetonitrile in water for 5 min. The flow rate was 1 ml min−1 throughout the process.

Northern blot analysis

Total cellular RNA was extracted using ISOGEN purchased from Nippon Gene, Toyama, Japan. The cDNA probes for human xCT and 4F2hc were labeled with [α-32P]dCTP using Rediprime™II random prime labelling system from Amersham Pharmacia Biotech (Little Chalfont, UK). Total RNA was electrophoresed on a 1% agarose gel in the presence of 2.2 M formaldehyde, transferred and hybridised as described previously (Sato et al, 1999).

Cell transfections

The inserts derived from mouse xCT and 4F2hc cDNAs were produced by PCR reaction using the primers containing mutations to generate appropriate restriction enzyme sites. The sequences of the primers used for PCR were 5′-CTCCTCAGATCTGACACTGCGCATGG-3′ and 5′-GATATCTCAATCTCTGGGCAGATGGCC-3′ for xCT, and 5′-GCCTCAGTACGATCTGTGCTG-3′ and 5′-GGAGGGTGTGTAAGCTTTGCATAGA-3′ for 4F2hc. The PCR products were cut out with BglII and HindIII and subcloned into pEGFP-C1 (BD Biosciences Clontech, Palo Alto, CA, USA). The sequences of the final constructs were verified by dideoxy-nucleotide sequencing. Transient transfections were performed using Lipofectamine Plus™ reagents (Invitrogen Corp., Carlsbad, CA, USA) according to the manufacturer’s instruction. A2780 cells were plated at 2.5 × 10^5 in a 35 mm diameter dish and cultured for 24 h. They were transfected for 3 h in Opti-MEM™ (Invitrogen corp., Carlsbad, CA, USA), and then the medium was changed to RPMI 1640 with 5% fetal bovine serum and they were incubated for further 33 h.

RESULTS

Characterisation of the cystine transport

As shown in Figure 1, the rate of cystine uptake was approximately 4.5-fold higher in A2780DDP than that in A2780. To characterise the transport system that mediates the cystine uptake, the rate of cystine uptake was measured in the presence of various amino acids in the uptake medium (Figure 1). In A2780 cells, the uptake of cystine was not inhibited significantly by the amino acids tested. In A2780DDP cells, the uptake of cystine was mostly Na+-independent and strongly inhibited by glutamate, but not by aspartate, leucine or arginine. The rate of cystine uptake in A2780DDP cells was significantly enhanced (about 1.7-fold increase) by DEM at a single exposure (Bannai, 1984). The rate of cystine uptake in A2780 cells was significantly enhanced (about 1.7-fold increase) by DEM at a single exposure (Bannai, 1984).
treatment for up to 6 months and the rate of cystine uptake was measured. The rate of cystine uptake decreased slightly but significantly after 6 months without CDDP treatment (Figure 2). Glutamate was a potent inhibitor of the cystine uptake throughout the experiment, indicating that A2780DDP cells preserve most of the system xc<sup>-</sup>/C<sub>0</sub> activity for at least 6 months in the absence of CDDP treatment. A2780DDP cells cultured without CDDP treatment for 6 months were tested to see whether they were still resistant to CDDP. When they were incubated with 50 μM CDDP for 24 h, viability was over 95% as judged by dye exclusion, which was nearly equal to that in the control A2780DDP cells. A2780 cells were heavily injured (approximately 5% viable) under such conditions.

Intracellular GSH levels

A2780 and A2780DDP cells were incubated for up to 24 h with 50 μM of buthionine sulfoximine (BSO), which inhibits the GSH synthesis, and the intracellular GSH was measured (Figure 3). The intracellular GSH level before the incubation with BSO was 1.8-fold higher (P<0.01) in A2780DDP (52.5 ± 1.9 nmol per mg protein) than that of A2780 (28.9 ± 2.1 nmol per mg protein). The results are consistent with those reported previously (Goto et al, 1995). GSH decreased time dependently and the half-life of intracellular GSH was estimated to be approximately 8–10 h in both cells (Figure 3). Changes in GSH level in the cells incubated for 24 h with excess amino acids were measured (Figure 4). Since cystine concentration in RPMI 1640 is considerably high (0.2 mM), we used cystine-restricted RPMI 1640 (cystine = 0.05 mM) to magnify a possible effect of the amino acids. In A2780DDP cells, the GSH level markedly decreased in the presence of excess glutamate but did not decrease in the presence of excess aspartate or leucine. A slight but significant decrease of an obscure origin was observed in the presence of excess arginine. In A2780 cells, the GSH level did not decrease even in the presence of glutamate. Then, A2780DDP cells were cultured without CDDP treatment for 3 or 6 months, and the intracellular GSH level was measured. The GSH level remained unchanged during six months without CDDP treatment (data not shown).

Intracellular cysteine levels

Intracellular cysteine level in A2780 and A2780DDP is shown in Figure 5. It was much higher (about 4.2-fold) in the resistant cells than in the sensitive cells. The result suggests that the high content of intracellular GSH in A2780DDP cells is accounted for by the increase in the intracellular content of cysteine, which is a rate-limiting substrate for the GSH synthesis.

Expression of xCT and 4F2hc mRNAs

Expression of xCT and 4F2hc mRNAs in A2780 and A2780DDP was examined by Northern blot analysis (Figure 6). xCT mRNA was hardly detectable in A2780 cells, whereas it was clearly expressed in A2780DDP cells. mRNA for 4F2hc was expressed in both cells, although more strongly in the resistant cells. 4F2hc is not only the component of system xc<sup>-</sup> but also that of some other heterodimeric amino-acid transporters (Palacin et al, 1998). IMR-90 human fibroblasts exhibit very high system xc<sup>-</sup> activity and are employed as a positive control. The results clearly showed that
system $x_c$ was transcriptionally activated in the CDDP-resistant cells.

**CDDP resistance of A2780 cells with xCT expression**

A2780 cells were transiently transfected with cDNAs of xCT and 4F2hc and the rate of uptake of cystine and CDDP resistance were examined. As shown in Figure 7A, the rate of uptake in these transfectant cells increased more than twice, and this increased uptake was inhibitable by excess glutamate (data not shown). The cells transfected with the cDNAs were significantly more resistant to CDDP than the control cells (Figure 7B). However, the system $x_c$ activity in these transfectants was much lower than that of A2780DDP cells and concomitantly they were less resistant to CDDP than A2780DDP cells. The viability of A2780DDP cells was over 95% when they were incubated in 50 μM CDDP for 24 h.

**Cystine transport activity in human colonic cancer cells**

As shown in Figure 8, the rate of cystine uptake was also higher in CDDP-resistant cells derived from human colonic cancer (HCT8DDP cells) than that in the sensitive cells (HCT8 cells). The cystine uptake in HCT8DDP cells was inhibited by glutamate. In the colonic cancer cell lines, unlike the ovarian cancer cells, inhibitory effect of glutamate was observed also in the sensitive cells, indicating the significant occurrence of system $x_c$ in HCT8 cells, although its activity is much lower than that of HCT8DDP cells.

**DISCUSSION**

Cystine is transported by system $x_c$ in the same ionic form as is glutamate, that is, in an anionic form (Bannai and Kitamura, 1981). Homocysteate and $\gamma$-amino adipate share the transport system but aspartate is not a good substrate. Within physiological pH, cystine occurs as a tetrapolar (neutral as a whole) ion in the main and as a tri- and dipolar (anionic as a whole) ion for the rest and the latter is the substrate for system $x_c$. System $x_c$ is an exchange agency and the physiologic flows via this system are the entry of cystine...
transport system for cystine identified in mammalian plasma is competitively inhibited by the extracellular glutamate. Another transport system for intracellular neutral (dipolar) amino acids (Palacin et al., 1998). The cystine uptake via this system is competitively inhibited by the extracellular cationic amino acid. Ubiquitous transport systems for neutral amino acids, systems \( A, \text{ASC and} L \), usually mediate the transport of dipolar form of the amino acids and cystine is far less reactive with these systems. In the present study, characteristics of the cystine uptake and the expression of xCT and 4F2hc mRNAs in CDDP-resistant cells clearly showed that the cystine uptake in these cells is largely mediated by system \( xc^- \). As shown in Figure 1, the cystine uptake in A2780DDP cells was not inhibited at all by arginine indicating no contribution of system \( b^\text{H}^- \). The CDDP-sensitive A2780 cells also took up cystine, although the rate was much lower than that of the resistant cells (Figure 1). The cystine uptake in A2780 cells was not significantly inhibited by any of the amino acids tested. Thus, neither system \( xc^- \) nor system \( b^\text{H}^- \) mediated the cystine uptake in A2780 cells. At present a transporter, if any, by which cystine is taken up in A2780 cells is unidentified. In HCT8 cells, cystine transport activity was significantly inhibited by glutamate (Figure 8), indicating the occurrence of system \( xc^- \) in these cells, although the resistant variant (HCT8DDP) had a much higher activity of this system.

In the present study, we have found a great increase of cystine transport activity in CDDP-resistant cells (A2780DDP). In these cells, the GSH levels were significantly higher than those in A2780 cells (Figures 3 and 4) and the drastic decrease in GSH by glutamate, a competitive inhibitor of the cystine uptake, indicates that system \( xc^- \) mainly contributes to the high level of GSH in A2780DDP cells. When the GSH synthesis was inhibited by BSO, the half-life of intracellular GSH was nearly equal in both cells (Figure 3). This means that the difference of GSH content in the CDDP-sensitive cells and the CDDP-resistant cells is mainly accounted for by the difference of GSH synthetic rate. The intracellular cysteine level was much higher in A2780DDP cells than in A2780 cells (Figure 8) most probably because of the enhanced uptake of cystine in the former cells. The concentration of cystine in A2780 cells and A2780DDP cells can be estimated to be approximately 0.11 and 0.46 mM, respectively, assuming that 1 mg cell protein is equivalent to 5 µl cell water. The reported value for \( K_m \) of \( \gamma \)-GCS for cysteine is 0.35 mM (Richman and Meister, 1975). Therefore, the rate of GSH synthesis depends almost linearly on the intracellular cysteine level in both A2780 cells and A2780DDP cells. The activity of \( \gamma \)-GCS is about two-fold higher in A2780DDP cells than in A2780 cells (Goto et al., 1995; Iida et al., 1999). It is, thus, reasonably concluded that the high GSH content in CDDP-resistant cells results from the induction of both the system \( xc^- \) and the enzyme \( \gamma \)-GCS and the former contributes more largely to the elevated GSH content than the latter. Despite the considerable increase in both the transport and the enzyme activities, GSH content in A2780DDP cells did not get further than twice in A2780 cells (Figures 3 and 4). This may be accounted for by a feedback inhibition of GSH synthesis by GSH. Goto et al. (1995) shown that the export of CDDP-GSH adduct was elevated (about 20% increase) in the resistant cells. The value is not large, yet the enhanced export may strengthen the CDDP resistance associated with GSH.

In A2780 cells, the cystine transport activity was not induced by a single exposure to CDDP. In contrast, the cystine transport activity was induced significantly by DEM with the similar treatment. It is obvious that the response to CDDP is quite different from that to DEM. The system \( xc^- \) activity is induced by electrophilic agents like DEM and reaches maximal level at about 48 h (Bannai, 1984). The activity reverts to the original level within 2–3 days if the agent is withdrawn. In contrast, to acquire CDDP resistance the cells are repeatedly treated with CDDP for a long time (Timmer-Bosscha et al., 1993). Actually, the sensitive cells are incubated with CDDP for 1 h at a dose inducing approximately 90% cell death and subsequently cultured in fresh medium. After cells are recovered, this treatment is repeated with a stepwise increasing dose of CDDP. It takes about 3–4 weeks for the cell recovery and a long period, about 1 year is required to obtain the CDDP-resistant cell line. Presumably, the cells are selected and acquire the stable and high expression of system \( xc^- \) during this.

**Figure 7** Uptake of cystine and CDDP resistance in A2780 cells transfected with cDNAs for xCT and 4F2hc. A2780 cells were cultured in the dish for 24 h and then they were transfected with pEGFP-C1 (Control) or cotransfected with pEGFP-C1/4F2hc and pEGFP-C1/xCT (xC) using Lipofectamine Plus™. After transfection, the cells were incubated for 33 h and the rate of cystine (0.05 mM) uptake was measured (A) or CDDP resistance was examined (B). CDDP resistance was estimated by measuring viability of the cells treated with 50 µM CDDP in fresh medium for the time indicated. Values are means ± s.d. (n = 6). *Significantly greater than the corresponding control, P < 0.01.

**Figure 8** Uptake of cystine in HCT8 and HCT8DDP cells. HCT8 cells (open bars) and HCT8DDP cells (filled bar) were cultured in the dish for 24 h and then the rate of cystine (0.05 mM) uptake was measured in the presence or absence of 2.5 mM of glutamate. Values are means ± s.d. (n = 4). *P < 0.01.
long and repeated exposure to CDDP. In some CDDP-resistant ovarian cancer cell lines, a large number of genetic changes probably associated with the development of CDDP resistance were found (Wasenius et al., 1997). The enhanced system x_c-activity may result from the genetic changes that occurred in CDDP-resistant cells. Recently several genes, which are differentially expressed in association with CDDP resistance, have been identified (Johnsson et al., 2000). Among them the genes highly expressed in the resistant cells include cytochrome oxidase I, ribosomal protein 28S, elongation factor 1x, α-enolase, stathmin and HSP70. The gene for xCT is a novel one and is worthy of note in these studies hereafter.

ACKNOWLEDGEMENTS

This work was supported by grants from the Ministry of Education, Culture and Science in Japan (HS and SB) and from the University of Tsukuba Project Research. We thank Dr Takeshi Kubo for his helpful discussion.

REFERENCES

Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35 – 43

Bannai S (1984) Induction of cystine and glutamate transport activity in human fibroblasts by diethyl maleate and other electrophilic agents. J Biol Chem 259: 2435 – 2440

Bannai S (1986) Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J Biol Chem 261: 2256 – 2263

Bannai S, Ishii T (1982) Transport of cystine and cysteine and cell growth in cultured human diploid fibroblasts: effect of glutamate and homocysteate. J Cell Physiol 112: 265 – 272

Bannai S, Kitamura E (1980) Transport interaction of L-cystine and L-cysteate. J Cell Physiol 101: 2372 – 2376

Bannai S, Kitamura E (1981) Role of proton dissociation in the transport of cystine and glutamate in human diploid fibroblasts in culture. J Biol Chem 256: 5770 – 5772

Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKay WM, Young RC, Ozols RF (1987) Characterization of a cis-diaminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414 – 418

Christensen HN (1990) Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 70: 43 – 77

Cotgreave IA, Moldeus P (1986) Methodologies for the application of monobromobimane to the simultaneous analysis of soluble and protein thiol components of biological systems. J Biochem Biophys Methods 13: 231 – 249

Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070 – 3074

Goto S, Yoshida K, Morikawa T, Urata Y, Suzuki K, Kondo T (1995) Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res 55: 4297 – 4301

Iida T, Mori E, Mori K, Goto S, Urata Y, Oka M, Kohno S, Kondo T (1999) Co-expression of gamma-glutamylcysteine synthetase sub-units in response to cisplatin and doxorubicin in human cancer cells. Int J Cancer 82: 405 – 411

Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC (1997) Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57: 850 – 856

Johnsson A, Zeelenberg I, Min Y, Hilinsky J, Berry C, Howell SB, Los G (2000) Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer 83: 1047 – 1054

Li Q, Tsang B, Bostick-Bruton F, Reed E (1999) Modulation of excision repair cross-complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol 57: 347 – 353

Meister A (1988) Glutathione metabolism and its selective modification. J Biol Chem 263: 17205 – 17208

Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215 – 220

Palacin M, Estevez R, Bertran J, Zorzano A (1998) Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev 78: 969 – 1054

Patterson Jr MK (1979) Measurement of growth and viability of cells in culture. Method Enzymol 58: 141 – 152

Perez RP, Hamilton TC, Ozols RF, Young RC (1993) Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 71: 1571 – 1580

Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331 – 344

Richman PG, Meister A (1975) Regulation of γ-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione. J Biol Chem 250: 1422 – 1426

Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55: 2303 – 2316

Sato H, Tamba M, Ishii T, Bannai S (1999) Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 274: 11455 – 11458

Sato H, Tamba M, Kuriyama-Matsumura K, Okuno S, Bannai S (2000) Molecular cloning and expression of human xCT, the light chain of amino acid transport system xc. Antioxid Redox Signal 2: 665 – 671

Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27: 502 – 522

Timmer-Bosscha H, Timmer A, Meijer C, de Vries EG, de Jong B, Oosterhuis JW, Mulder NH (1993) cis-Diaminedichloroplatinum(II) resistance in vitro and in vivo in human embryonal carcinoma cells. Cancer Res 53: 5707 – 5713

Toohey JJ (1975) Sulphhydril dependence in primary explant hematopoietic cells. Inhibition of growth in vitro with vitamin B12 compounds. Proc Natl Acad Sci USA 72: 73 – 77

Wasenius VM, Jekunen A, Monni O, Joensuu H, Aebi S, Howell SB, Knuttila S (1997) Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells. Genes Chromosomes Cancer 18: 286 – 291

Yao KS, Godwin AK, Johnson SW, Ozols RF, O’Dwyer PJ, Hamilton TC (1995) Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55: 4367 – 4374